首页 > 抗体蛋白 > 抗体
PE anti-mouse IL-2 Antibody
产品名称:
PE anti-mouse IL-2 Antibody
产品类别:
抗体
产品编号:
503807
产品应用:
503807
[价格]
规格 价格 库存
25µg ¥ 996 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IL-2
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Detection1-3 or ELISPOT Detection4-6: The biotinylated JES6-5H4 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified JES6-1A12 antibody (Cat. Nos. 503701 & 503702) as capture antibody and recombinant mouse IL-2 (Cat. No. 575409) as the standard.
Flow Cytometry8-10: The fluorochrome-labeled JES6-5H4 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-2 -producing cells within mixed cell populations.
Neutralization1,7: The Ultra-LEAF? purified antibody (Endotoxin in vivo and in vitro (Cat. No. 503845-503850)) is recommended for neutralization.
Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections2, in vivo capture7, and immunocytochemistry.
Note: For testing mouse IL-2 in serum, plasma or supernatant, BioLegend's ELISA MAX? Sets (Cat. No. 431001 & 431004) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
  3. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.
  4. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19.
  5. Mo X, et al. 1995. J. Virol. 69:1288.
  6. Karulin A, et al. 2000. J. Immunol. 164:1862.
  7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. PubMed
  9. Kang SS and Allen PM. 2005. J. Immunol. 174:5382.
  10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
Product Citations
  1. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  2. Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed
  3. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  4. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  5. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  6. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  7. Page N, et al. 2018. Immunity. 48:937. PubMed
  8. Wei H, et al. 2021. Malar J. 20:89. PubMed
  9. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  10. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  11. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  12. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
  13. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  14. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  15. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  16. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  17. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  18. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  19. Tanaka Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  20. Shrivastava T, et al. 2021. Front Immunol. 12:641447. PubMed
  21. Marangoni F, et al. 2021. Cell. . PubMed
  22. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  23. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  24. Dolina JS, et al. 2020. Cell Rep. 107249:31. PubMed
  25. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  26. Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed
  27. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  28. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  29. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  30. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  31. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  32. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  33. White C, et al. 2015. J Immunol. 194:697. PubMed
  34. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  35. Ye X, et al. 2021. Cancer Biol Med. Online ahead of print. PubMed
  36. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  37. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  38. Ma K, et al. 2022. iScience. 25:104347. PubMed
  39. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  40. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  41. Majedi FS, et al. 2020. Biomaterials. 252:120058. PubMed
  42. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  43. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  44. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  45. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  46. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  47. Nanishi E, et al. 2022. Commun Biol. 5:790. PubMed
  48. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  49. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  50. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  51. Haring J, et al. 2008. J Immunol. 180:2855. PubMed
  52. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  53. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  54. Li J, et al. 2021. Cell Reports. 34(11):108839. PubMed
  55. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  56. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  57. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  58. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  59. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  60. Liu Z, et al. 2022. Int J Nanomedicine. 17:1711. PubMed
  61. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
RRID
AB_315301 (BioLegend Cat. No. 503807) AB_315302 (BioLegend Cat. No. 503808)

Antigen Details

Structure
Cytokine; 15-30 kD (Mammalian)
Bioactivity
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources
T cells
Cell Targets
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type
Tregs
Biology Area
Immunology
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Taniguchi T, et al. 1993. Cell 73:5.
3. Nistico G. 1993. Prog. Neurobiol. 40:463.
4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.

Regulation
Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID
16183 View all products for this Gene ID
UniProt
View information about IL-2 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线